SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/28/22 Pacira BioSciences, Inc. 10-K 12/31/21 128:17M |
Document/Exhibit Description Pages Size 1: 10-K 10-K - Pcrx - 12.31.2021 HTML 1.80M 2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 497K 3: EX-4.5 Instrument Defining the Rights of Security Holders HTML 51K 4: EX-10.3 Material Contract HTML 44K 6: EX-10.36 Material Contract HTML 276K 7: EX-10.37 Material Contract HTML 161K 8: EX-10.38 Material Contract HTML 38K 5: EX-10.4 Material Contract HTML 45K 9: EX-21.1 Subsidiaries List HTML 33K 10: EX-23.1 Consent of Expert or Counsel HTML 31K 11: EX-31.1 Certification -- §302 - SOA'02 HTML 35K 12: EX-31.2 Certification -- §302 - SOA'02 HTML 35K 13: EX-32.1 Certification -- §906 - SOA'02 HTML 33K 19: R1 Cover HTML 96K 20: R2 Audit Information HTML 36K 21: R3 Consolidated Balance Sheets HTML 155K 22: R4 Consolidated Balance Sheets (Parenthetical) HTML 49K 23: R5 Consolidated Statements of Operations HTML 132K 24: R6 Consolidated Statements of Comprehensive Income HTML 58K (Loss) 25: R7 Consolidated Statements of Stockholders' Equity HTML 118K 26: R8 Consolidated Statements of Stockholders' Equity HTML 33K (Parenthetical) 27: R9 Consolidated Statements of Cash Flows HTML 166K 28: R10 Description of Business HTML 39K 29: R11 Summary of Significant Accounting Policies HTML 80K 30: R12 Recent Accounting Pronouncements HTML 49K 31: R13 Revenue HTML 88K 32: R14 Acquisitions HTML 79K 33: R15 Inventories HTML 40K 34: R16 Fixed Assets HTML 46K 35: R17 Leases HTML 60K 36: R18 Goodwill and Intangible Assets HTML 62K 37: R19 Accrued Expenses HTML 45K 38: R20 Debt HTML 110K 39: R21 Financial Instruments HTML 122K 40: R22 Stockholders' Equity HTML 56K 41: R23 Stock Plans HTML 138K 42: R24 Net Income (Loss) Per Share HTML 64K 43: R25 Income Taxes HTML 117K 44: R26 Employee Benefit Plans HTML 38K 45: R27 Acquisition-Related Charges and Product HTML 60K Discontinuation, Net 46: R28 Commercial Partners and Other Agreements HTML 44K 47: R29 Related Party Transactions HTML 34K 48: R30 Commitments and Contingencies HTML 50K 49: R31 Subsequent Events HTML 33K 50: R32 Summary of Significant Accounting Policies HTML 151K (Policies) 51: R33 Summary of Significant Accounting Policies HTML 60K (Tables) 52: R34 Revenue (Tables) HTML 78K 53: R35 Acquisitions (Tables) HTML 69K 54: R36 Inventories (Tables) HTML 41K 55: R37 Fixed Assets (Tables) HTML 47K 56: R38 Leases (Tables) HTML 60K 57: R39 Goodwill and Intangible Assets (Tables) HTML 62K 58: R40 Accrued Expenses (Tables) HTML 43K 59: R41 Debt (Tables) HTML 79K 60: R42 Financial Instruments (Tables) HTML 113K 61: R43 Stockholders' Equity (Tables) HTML 51K 62: R44 Stock Plans (Tables) HTML 145K 63: R45 Net Income (Loss) Per Share (Tables) HTML 65K 64: R46 Income Taxes (Tables) HTML 113K 65: R47 Acquisition-Related Charges and Product HTML 50K Discontinuation, Net (Tables) 66: R48 Description of Business (Details) HTML 35K 67: R49 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 47K Concentration of Major Customers (Details) 68: R50 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Fixed HTML 42K Assets (Details) 69: R51 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 51K Narrative (Details) 70: R52 Recent Accounting Pronouncements (Details) HTML 42K 71: R53 REVENUE - Sales and Valuation Accruals (Details) HTML 56K 72: R54 REVENUE - Narrative (Details) HTML 36K 73: R55 REVENUE- Disaggregation (Details) HTML 45K 74: R56 ACQUISITIONS - Narrative (Details) HTML 106K 75: R57 ACQUISITIONS - Contingent Consideration Flexion HTML 47K Acquisition (Details) 76: R58 ACQUISITIONS - Schedule of Assets and Liabilities HTML 87K Acquired (Details) 77: R59 ACQUISITIONS - Flexion Results (Details) HTML 37K 78: R60 ACQUISITIONS - Schedule of Pro Forma Information HTML 42K (Details) 79: R61 INVENTORIES - Components of Inventory (Details) HTML 41K 80: R62 FIXED ASSETS - Schedule of Useful Lives (Details) HTML 51K 81: R63 FIXED ASSETS - Narrative (Details) HTML 45K 82: R64 LEASES - Narrative (Details) HTML 41K 83: R65 LEASES - Summary of operating lease cost and other HTML 48K operating lease information (Details) 84: R66 LEASES - Schedule of maturities of operating lease HTML 50K liabilities (Details) 85: R67 GOODWILL AND INTANGIBLE ASSETS - Goodwill HTML 43K (Details) 86: R68 GOODWILL AND INTANGIBLE ASSETS - Narrative HTML 60K (Details) 87: R69 GOODWILL AND INTANGIBLE ASSETS - Intangible Assets HTML 55K (Details) 88: R70 Accrued Expenses (Details) HTML 54K 89: R71 DEBT - Carrying Value of Debt (Details) HTML 57K 90: R72 DEBT - Narrative (Details) HTML 264K 91: R73 DEBT - Schedule of Debt (Details) HTML 62K 92: R74 DEBT - Schedule of Interest Expense (Details) HTML 48K 93: R75 FINANCIAL INSTRUMENTS - Fair Value of Liabilities HTML 96K Measured on a Recurring Basis (Details) 94: R76 FINANCIAL INSTRUMENTS - Narrative (Details) HTML 141K 95: R77 FINANCIAL INSTRUMENTS - Schedule of Fair Value HTML 49K Inputs and Valuation (Details) 96: R78 FINANCIAL INSTRUMENTS - Contingent Consideration HTML 42K Rollforward (Details) 97: R79 FINANCIAL INSTRUMENTS - Schedule of Investments at HTML 62K Amortized Cost and Fair Value (Details) 98: R80 STOCKHOLDERS' EQUITY - Narrative (Details) HTML 44K 99: R81 Stockholders' Equity - Aoci (Details) HTML 51K 100: R82 STOCK PLANS - Narrative (Details) HTML 61K 101: R83 STOCK PLANS - Stock Incentive Plans (Details) HTML 52K 102: R84 STOCK PLANS - Compensation Expense (Details) HTML 50K 103: R85 STOCK PLANS - Stock Option Activity (Details) HTML 93K 104: R86 STOCK PLANS - Valuation Assumptions (Details) HTML 56K 105: R87 STOCK PLANS - RSU Activity (Details) HTML 61K 106: R88 Net Income (LOSS) PER SHARE - Calculation HTML 81K (Details) 107: R89 Net Income (LOSS) PER SHARE - Antidilutive HTML 41K Securities (Details) 108: R90 INCOME TAXES - Narrative (Details) HTML 110K 109: R91 INCOME TAXES - Current and Deferred Income Taxes HTML 66K (Details) 110: R92 INCOME TAXES - Reconciliation of Effective Tax HTML 62K Rate (Details) 111: R93 INCOME TAXES - Deferred Tax Assets and Liabilities HTML 64K (Details) 112: R94 INCOME TAXES - Unrecognized Tax Benefits (Details) HTML 38K 113: R95 Employee Benefit Plans (Details) HTML 48K 114: R96 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 59K DISCONTINUATION, NET - Product Discontinuance (Details) 115: R97 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 46K DISCONTINUATION, NET - Flexion (Details) 116: R98 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 43K DISCONTINUATION, NET - MyoScience (Details) 117: R99 Acquisition-Related Charges and Product HTML 35K Discontinuation, Net - Nuance (Details) 118: R100 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 36K DISCONTINUATION, NET - DepoCyte Discontinuation (Details) 119: R101 ACQUISITION-RELATED CHARGES AND PRODUCT HTML 33K DISCONTINUATION, NET - Department of Justice (Details) 120: R102 Commercial Partners and Other Agreements (Details) HTML 57K 121: R103 Related Party Transactions (Details) HTML 41K 122: R104 Commitments and Contingencies (Details) HTML 67K 123: R105 Subsequent Events (Details) HTML 44K 126: XML IDEA XML File -- Filing Summary XML 225K 124: XML XBRL Instance -- pcrx-20211231_htm XML 3.44M 125: EXCEL IDEA Workbook of Financial Reports XLSX 176K 15: EX-101.CAL XBRL Calculations -- pcrx-20211231_cal XML 315K 16: EX-101.DEF XBRL Definitions -- pcrx-20211231_def XML 1.42M 17: EX-101.LAB XBRL Labels -- pcrx-20211231_lab XML 2.82M 18: EX-101.PRE XBRL Presentations -- pcrx-20211231_pre XML 1.84M 14: EX-101.SCH XBRL Schema -- pcrx-20211231 XSD 293K 127: JSON XBRL Instance as JSON Data -- MetaLinks 640± 929K 128: ZIP XBRL Zipped Folder -- 0001396814-22-000021-xbrl Zip 1.07M
Document |
Date: | February 28, 2022 | /s/ CHARLES A. REINHART, III | ||||||
Chief Financial Officer (Principal Financial Officer) |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 2/28/22 | 4 | ||
For Period end: | 12/31/21 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Pacira BioSciences, Inc. 10-K 12/31/23 123:17M 2/28/23 Pacira BioSciences, Inc. 10-K 12/31/22 118:16M 11/03/22 Pacira BioSciences, Inc. 10-Q 9/30/22 90:11M 8/04/22 Pacira BioSciences, Inc. S-8 8/04/22 5:116K 8/03/22 Pacira BioSciences, Inc. 10-Q 6/30/22 90:10M 5/04/22 Pacira BioSciences, Inc. 10-Q 3/31/22 92:9.5M |